Nanospectra Biosciences

OverviewSuggest Edit

Nanospectra Biosciences is a company specializing in nanomedicine for selective thermal ablation. It offers AuroLase ultra-focal therapy device to treat solid tumors without damaging adjacent healthy tissue.
TypePrivate
Founded2002
HQHouston, TX, US
Websitenanospectra.com

Latest Updates

Employees (est.) (Nov 2021)9
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Nanospectra Biosciences

David Jorden

David Jorden

CEO and Director
Glenn P. Goodrich

Glenn P. Goodrich

COO & Vice President, Process Development & Chemistry
Michael Brawer

Michael Brawer

Chief Medical Officer
Patrick W. Pace

Patrick W. Pace

Chairman of the Board
Jon Schwartz

Jon Schwartz

Director, Clinical Research
Show more

Nanospectra Biosciences Office Locations

Nanospectra Biosciences has an office in Houston
Houston, TX, US (HQ)
8285 El Rio St #150
Show all (1)

Nanospectra Biosciences Financials and Metrics

Summary Metrics

Founding Date

2002

Nanospectra Biosciences total Funding

$4.3 m

Nanospectra Biosciences latest funding size

$2 m

Time since last funding

5 years ago
Nanospectra Biosciences's latest funding round in February 2017 was reported to be $2 m. In total, Nanospectra Biosciences has raised $4.3 m
Show all financial metrics

Nanospectra Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Nanospectra Biosciences Online and Social Media Presence

Embed Graph

Nanospectra Biosciences News and Updates

Nanospectra Biosciences Announces Enrollment Completion of Pivotal Study of AuroLase Therapy for Ablation of Prostate Tissue

End of Study Top-line Data Available Late-2022 End of Study Top-line Data Available Late-2022

Nanospectra Biosciences Raises First Tranche of Series B-1 Funding Led by Sirtex Medical

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that it has closed on an initial $3 million in a Series B-1 financing with total approved capital of up to $6 million in the raise. The equity round was led …

Nanospectra Biosciences Announces Four Additional Prestigious Trial Sites for Pivotal AuroLase Study

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the addition of four clinical trial sites to its ongoing AuroLase® pivotal study

Nanospectra Biosciences Initiates Pivotal Study of AuroLase Therapy for Ablation of Prostate Tissue

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the start of a pivotal study to determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanopartic…

Nanospectra Biosciences Frequently Asked Questions

  • When was Nanospectra Biosciences founded?

    Nanospectra Biosciences was founded in 2002.

  • Who are Nanospectra Biosciences key executives?

    Nanospectra Biosciences's key executives are David Jorden, Glenn P. Goodrich and Michael Brawer.

  • How many employees does Nanospectra Biosciences have?

    Nanospectra Biosciences has 9 employees.

  • Who are Nanospectra Biosciences competitors?

    Competitors of Nanospectra Biosciences include Dare Bioscience, TransGenex Nanobiotech and Co-D Therapeutics.

  • Where is Nanospectra Biosciences headquarters?

    Nanospectra Biosciences headquarters is located at 8285 El Rio St #150, Houston.

  • Where are Nanospectra Biosciences offices?

    Nanospectra Biosciences has an office in Houston.

  • How many offices does Nanospectra Biosciences have?

    Nanospectra Biosciences has 1 office.